Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
AUTOR(ES)
Massoud, Mira Romany, Caimi, Paolo Fabrizio, Ferrari, Nicole, Fu, Pingfu, Creger, Richard, Fox, Robert, Carlson-Barko, Joanne, Kolk, Merle, Brister, Lauren, Cooper, Brenda Wimpfheimer, Gerson, Stanton, Lazarus, Hillard Michael, Lima, Marcos de, William, Basem Magdy
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2016-12
RESUMO
ABSTRACT Introduction: Allogeneic hematopoietic stem cell transplantation offers the opportunity for extended survival in patients with Hodgkin's and non-Hodgkin lymphomas who relapsed after, or were deemed ineligible for, autologous transplantation. This study reports the cumulative experience of a single center over the past 14 years aiming to define the impact of patient, disease, and transplant-related characteristics on outcomes. Methods: All patients with histologically confirmed diagnosis of Hodgkin's or non-Hodgkin lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively studied. Results: Forty-one patients were reviewed: 10 (24%) had Hodgkin's and 31 (76%) had non-Hodgkin lymphomas. The median age was 50 years and 23 (56%) were male. The majority of patients (68%) had had a prior autologous transplantation. At the time of allogeneic transplantation, 18 (43%) patients were in complete and seven (17%) were in partial remission. Most (95%) patients received reduced-intensity conditioning, 49% received matched sibling donor grafts, 24% matched-unrelated donor grafts, and 27% received double umbilical cord blood grafts. The 100-day treatment-related mortality rate was 12%. After a median duration of follow up of 17.1 months, the median progression-free and overall survival was 40.5 and 95.8 months, respectively. On multivariate analysis, patients who had active disease at the time of transplant had inferior survival. Conclusions: Allogeneic transplantation results extend survival in selected patients with relapsed/refractory Hodgkin's and non-Hodgkin lymphomas with low treatment-related mortality. Patients who have active disease at the time of allogeneic transplantation have poor outcomes.
Documentos Relacionados
- Simultaneous pancreatectomy and liver transplantation: a single-institution experience
- Renal transplantation for patients 60 years of older. A single-institution experience.
- Surgical management of adrenal cysts: a single-institution experience
- Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.
- Unrelated hematopoietic stem cell transplantation in the pediatric population: single institution experience